Home >> Pharmaceuticals >> Food & Beverage >>

CytRx Corporation - Product Pipeline Review - 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 44 | Code: MRS - 18305

CytRx Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘CytRx Corporation - Product Pipeline Review - 2015’, provides an overview of the CytRx Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytRx Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CytRx Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CytRx Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the CytRx Corporation’s pipeline products

Reasons to buy

- Evaluate CytRx Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CytRx Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CytRx Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CytRx Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytRx Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CytRx Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
CytRx Corporation Snapshot 5
CytRx Corporation Overview 5
Key Information 5
Key Facts 5
CytRx Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
CytRx Corporation - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
CytRx Corporation - Pipeline Products Glance 12
CytRx Corporation - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
CytRx Corporation - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
CytRx Corporation - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
CytRx Corporation - Drug Profiles 16
aldoxorubicin hydrochloride 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
bafetinib 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Cyt-HiPoA 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Cyt-PLAT 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CytRx Corporation - Pipeline Analysis 23
CytRx Corporation - Pipeline Products by Target 23
CytRx Corporation - Pipeline Products by Route of Administration 24
CytRx Corporation - Pipeline Products by Molecule Type 25
CytRx Corporation - Pipeline Products by Mechanism of Action 26
CytRx Corporation - Recent Pipeline Updates 27
CytRx Corporation - Dormant Projects 37
CytRx Corporation - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
INNO-305 38
tamibarotene 38
CytRx Corporation - Company Statement 39
CytRx Corporation - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables
CytRx Corporation, Key Information 5
CytRx Corporation, Key Facts 5
CytRx Corporation - Pipeline by Indication, 2015 7
CytRx Corporation - Pipeline by Stage of Development, 2015 8
CytRx Corporation - Monotherapy Products in Pipeline, 2015 9
CytRx Corporation - Partnered Products in Pipeline, 2015 10
CytRx Corporation - Partnered Products/ Combination Treatment Modalities, 2015 11
CytRx Corporation - Phase III, 2015 12
CytRx Corporation - Phase II, 2015 13
CytRx Corporation - Phase I, 2015 14
CytRx Corporation - Preclinical, 2015 15
CytRx Corporation - Pipeline by Target, 2015 23
CytRx Corporation - Pipeline by Route of Administration, 2015 24
CytRx Corporation - Pipeline by Molecule Type, 2015 25
CytRx Corporation - Pipeline Products by Mechanism of Action, 2015 26
CytRx Corporation - Recent Pipeline Updates, 2015 27
CytRx Corporation - Dormant Developmental Projects,2015 37
CytRx Corporation - Discontinued Pipeline Products, 2015 38
CytRx Corporation, Subsidiaries 42

List of Figures
CytRx Corporation - Pipeline by Top 10 Indication, 2015 7
CytRx Corporation - Pipeline by Stage of Development, 2015 8
CytRx Corporation - Monotherapy Products in Pipeline, 2015 9
CytRx Corporation - Partnered Products in Pipeline, 2015 10
CytRx Corporation - Pipeline by Top 10 Target, 2015 23
CytRx Corporation - Pipeline by Top 10 Route of Administration, 2015 24
CytRx Corporation - Pipeline by Top 10 Molecule Type, 2015 25
CytRx Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015 26

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing